Abstract
Huntington's Disease (HD) is an incurable neurodegenerative condition marked by the gradual decline of motor abilities, cognitive capabilities, and emotional stability. It results from a mutation in the Huntingtin gene (HTT), which triggers the generation of a harmful variant of the Huntingtin protein known as mutant Huntingtin (mHTT). Despite significant advancements in understanding the disease's molecular basis, effective treatments to halt or reverse its progression remain elusive. Over the past few years, the groundbreaking genetic modification technique called Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) has risen as a hopeful tool in the realm of genetic investigation and treatment. CRISPR has the potential to precisely target and modify specific genes, offering new possibilities for the treatment of Huntington's Disease. This paper aims to provide an overview of Huntington's Disease, the CRISPR technology, and its potential applications in addressing the underlying genetic causes of HD. By exploring the fundamental aspects of both HD and CRISPR, this paper hopes to provide a clearer picture to the therapeutic potential of CRISPR in mitigating the effects of this neurodegenerative disorder.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
